AstraZeneca announced on Tuesday that its experimental monoclonal antibody treatment for COVID-19, also known as AZD7442, failed to hit the pharmaceutical giant’s primary aim of preventing symptoms in individuals who recently became exposed to the coronavirus disease.
The company said that the volunteers involved in its Phase III trial were unvaccinated adults older than 18 years with confirmed exposure to a person infected with coronavirus within the past eight days.
According to AstraZeneca, the antibody therapy that it has been formulating was able to reduce the risk of developing symptomatic COVID-19 by 33 percent among all exposed participants – including the ones who tested negative after exposure – compared to a placebo.
However, the study results failed to meet the primary goal that the treatment needed to achieve so that it can be effective enough to prevent symptoms in people exposed to the coronavirus.
The results, which were also deemed statistically insignificant by AstraZeneca itself, have stirred up concerns from medical experts and other people who have been hoping for a therapeutic treatment for Covid-19 for unvaccinated people.
“While this trial did not meet the primary endpoint against symptomatic illness, we are encouraged by the protection seen in the PCR negative participants following treatment with AZD7442,” Mene Pangalos, a British neuroscientist and Executive Vice President at AstraZeneca, said in a statement.
“We await results from PROVENT, our pre-exposure prevention trial and TACKLE, our treatment trial in preventing more severe disease, to understand the potential role of AZD7442 in protecting against COVID-19,” he added.
© Fourth Estate® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.